Table 3 Secondary endpoint of GvHD outcomes after receiving SARS-CoV2 vaccination
| Â | Value | p value |
|---|---|---|
Incidence of GvHD relative to transplant date, n (%) | ||
 0–180 days | 10/33 (30.3) | 0.012 |
 180–365 days | 8/57 (14.0) |  |
 > 365 days | 23/208 (11.6) |  |
Incidence of GvHD based on prior GvHD prior to vaccine | ||
 Yes | 33/187 (17.6) | 0.011 |
 No | 8/111 (7.2) |  |
Incidence of GvHD based on systemic immunosuppressant use prior to vaccine, n (%) | ||
 Yes | 20/119 (16.8) | 0.213 |
 No | 21/179 (11.7) |  |